Somatostatin Receptor Ligand

SCHEMBL16062971

C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)C(CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1 SSTR2 SSTR3 SSTR4 SSTR5

The experimentally established mechanism targets of Somatostatin Receptor Ligand. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SSTR4 known ✓	P31391	13/20	0.83

▸	SSTR1 known ✓	P30872	11/20	0.83

▸	SSTR2 known ✓	P30874	10/20	0.83

▸	SSTR5 known ✓	P35346	10/20	0.83

▸	SSTR3 known ✓	P32745	10/20	0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Somatostatin Receptor Ligand SCHEMBL16186775	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
SCHEMBL29368491	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin SCHEMBL29350200	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL12548326	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL31432768	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL29386529	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL8482	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL3046327	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin SCHEMBL21361053	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL3839184	1.00	SSTR4 (0.83)	SSTR4SSTR1SSTR2SSTR5SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9579364-B2	Methods for treating benign prostatic hypertrophy (BPH)	NEW YORK UNIVERSITY (US)	2017-02-28	—	—	US	disclosed
US-9408887-B2	Intermittent dosing regimen for treating breast cancer	NEW YORK UNIVERSITY (US)	2016-08-09	—	—	US	disclosed
US-20150099700-A1	METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF	NEW YORK UNIVERSITY	2015-04-09	—	—	US	disclosed
US-20140349937-A1	METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY (BPH)	UNITED STATES GOVERNMENT	2014-11-27	—	—	US	disclosed
US-8835123-B2	Methods for detecting progenitor cells and uses thereof	NEW YORK UNIVERSITY (US)	2014-09-16	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20140349937-A1	METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY (BPH)	BPHL, IGFBP1, IGFBP2	SSTR4 366/4885SSTR1 572/4885SSTR2 308/4885
US-20150099700-A1	METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF	BRCA1, TP53, PGR	SSTR4 3426/4885SSTR1 3900/4885SSTR2 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.